Bruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2008 2008 Highlights Q4-08 FY08 Revenue: $315.2 million $1.107 billion Operating Cash Flow: $86.5 million $105.5 million GAAP EPS per dilu

Bruker Corporation Reports Financial Results for the

Fourth Quarter and Full Year 2008

BILLERICA, Mass., March 3, 2009

(BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today

reported financial results for the fourth quarter and year ended December 31,

On February 26, 2008, Bruker BioSciences Corporation closed its

acquisition of the Bruker BioSpin Group, and renamed itself Bruker

Corporation. Under US GAAP, this

transaction is accounted for as an acquisition of businesses under common

control, and as a result all one-time transaction costs are expensed in the

period in which they are incurred, rather than being added to goodwill. In addition, expenses incurred subsequent to

the consummation of the acquisition, such as interest expenses incurred on

acquisition related debt, are not reflected in the financial results of periods

prior to the date of the acquisition, as they typically would be in pro-forma

financials in acquisitions of unrelated parties. After the closing of the transaction all

historical financial statements are required to be restated by combining the

historical consolidated financial statements of Bruker BioSciences Corporation

with those of the Bruker BioSpin Group.

Accordingly, the financial results for the three and twelve months ended

December 31, 2008 and 2007, included within this release, represent the

combined historical consolidated financial statements of Bruker BioSciences

Corporation with those of the Bruker BioSpin Group.

In the fourth quarter of 2008, revenue was

$315.2 million, compared to revenue of $344.8 in the fourth quarter of

2007. Excluding the effects of foreign

currency translation, fourth quarter revenue decreased by 3% year-over-year. Sequentially, revenues in the fourth quarter

of 2008 increased by 30%, compared to revenue of $242.1 million in the third

quarter of 2008. For the year 2008,

revenue increased by 7% to $1,107.1 million, compared to revenue of $1,032.4

million for the year 2007. Excluding the

effects of foreign currency translation, full year 2008 revenue increased by 3%

GAAP operating income in the fourth quarter

of 2008 was $48.9 million, compared to $66.4 million in the fourth quarter of

2007. For the year 2008, GAAP operating

income was $108.2 million, compared to $137.7 million for the year 2007. Including the adjustments in the attached

reconciliation, non-GAAP operating income in the fourth quarter of 2008 was

$52.6 million, compared to $74.0 million in the fourth quarter of

For the year 2008, non-GAAP operating income was $121.2 million,

compared to $147.3 million in 2007.

GAAP net income for the fourth quarter of

2008 was $26.2 million, or $0.16 per diluted share, compared to $40.3 million,

or $0.24 per diluted share, in the fourth quarter of 2007. For the year 2008, GAAP net income was $64.9

million, or $0.39 per diluted share, compared to $98.9 million, or $0.60 per

diluted share, in the year 2007.

Including the adjustments in the attached reconciliation, non-GAAP net income

for the fourth quarter of 2008 was $30.4 million, or $0.18 per diluted share,

compared to $47.7 million, or $0.29 per diluted share, in the fourth quarter of

2007. For the year 2008, non-GAAP net

income was $77.9 million, or $0.47 per diluted share, compared to $107.9

million, or $0.66 per diluted share, in 2007.

Cash flow from operations for the full year

2008 was $105.5 million, compared to $120.9 million in 2007. Free cash flow, defined as operating cash

flow less capital expenditures, was $58.1 million during 2008, compared to

$93.9 million during 2007. Capital

expenditures for the year 2008 were $47.4 million, which was approximately $20

million higher than in 2007 due to the expansion of two manufacturing locations

in 2008. During the year 2008, the

Company repaid $187.0 million of the debt incurred to finance the Bruker

BioSpin Group acquisition in February 2008. As of December 31, 2008, Bruker had cash

and cash equivalents of $167.7 million, and net debt of $56.1 million.

Frank Laukien, President and CEO, commented: Our

fourth quarter was again our strongest quarter of the year. In the fourth quarter of 2008, we had strong

new order bookings and we ended the year 2008 with a healthy backlog. However, in 2008 our margins were well below

our goals, and we have put aggressive cost-cutting initiatives in place, which

include voluntary top-management salary decreases for 2009, selected staff

reductions, hiring and salary freezes for 2009, and cut-backs in discretionary

spending. In addition, we continue to

drive numerous gross margin improvement projects, from which we expect to

benefit in 2009 and beyond.

Dr. Laukien continued with

an outlook for the year 2009: This year offers significant challenges due to

the deepening global recession and uncertain outlook. Bruker is relatively well positioned to deal

with these challenges, as we have an exceptionally strong technology, IP and

product portfolio and broad international diversification. Bruker also derives more than 60% of its

revenue from universities, medical schools, as well as other non-profit and

government customers, who tend to be less sensitive to economic

conditions. Some of our demand drivers

are even counter-cyclical, and a few of our customers have already begun to

benefit from counter-cyclical supplementary budgets and various national

Bruker s CFO Bill Knight

added: Financially, we expect to

continue to have a strong balance sheet, positive operating and free cash flow,

ample borrowing capacity, and clear opportunities to improve our margins,

balance sheet metrics and cash flow generation.

On this solid financial

foundation, we will invest further in our future, even during 2009, with

additional market development in attractive applied markets, including food and

consumer safety, pharma PAT, forensics and toxicology, as well as in clinical

research and IVD, homeland security and explosives detection, and advanced

superconducting magnets and devices.

Leveraging our strong technology base into these near-term additional

growth and margin opportunities makes strategic sense for Bruker, and we intend

to emerge from this recession as an even stronger company.

Mr. Knight continued: Given

the apparent further deterioration of the global economy in January and February 2009,

and the uncertainty of the timing and effect of various international stimulus

efforts, forecasting for the full year 2009 is extremely difficult. We have nevertheless established internal

financial goals for ourselves in 2009, and intend to drive Bruker towards:

currency-adjusted low single digit percentage decline in revenue or flat